Amylyx Pharmaceuticals (AMLX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec8

Amylyx Pharmaceuticals Presents Early Phase I Clinical Trial Results of ALS Drug AMX0114 at International Symposium

09:36

Dec5

Amylyx Pharmaceuticals Inc Announces Safety and Tolerability Data for AMX0114 in ALS

14:01

Nov6

Amylyx Pharmaceuticals released FY2025 9 Months earnings on November 6, Pre-Market (EST), actual revenue USD 0, actual EPS USD -1.2539

14:30

Amylyx Pharmaceuticals released FY2025 Q3 earnings on November 6 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3684 (forecast USD -0.4437)

14:30

Amylyx Pharmaceuticals Inc. Successfully Raised Funds Through IPO Extending Cash Flow

12:03

Amylyx Pharmaceuticals Reports Lower-than-Expected Third-Quarter Earnings

12:00

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -34.39 M, EPS -0.3684

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -41.44 M, EPS -0.4649

May8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -35.91 M, EPS -0.4189

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More